

## IN THE CLAIMS

Please amend the following claims:

- B1
1. (Amended) A stabilized pharmaceutical composition for the treatment of dyslipidemia, comprising
- an active component consisting essentially of one or more compounds selected from the group consisting of (i) a ring-opened 7-substituted-3,5-dihydroxyheptanoic acid or a pharmaceutically acceptable acid salt thereof, and (ii) a ring-opened 7-substituted-3,5-dihydroxyheptanoic acid or a pharmaceutically acceptable acid salt thereof, and
- a stabilizing effective amount of at least one amido-group containing polymeric compound or at least one amino-group containing polymeric compound, or combination thereof; wherein said stabilized pharmaceutical composition does not contain a stabilizing effective amount of another stabilizer or a combination of other stabilizers.

- B2
26. (Amended) A stabilized pharmaceutical composition for the treatment of dyslipidemia comprising, in admixture,
- (a) an active component consisting essentially of about 0.05% to about 70% by weight of one or more compounds selected from the group consisting of (i) a ring-opened 7-substituted 3,5-dihydroxyheptanoic acid or a pharmaceutically acceptable acid salt thereof or (ii) a ring-opened 7-substituted-3,5-dihydroxyheptanoic acid or a pharmaceutically acceptable acid salt thereof, and
- (b) about 30% to about 99% by weight of a stabilizing effective amount of an amido-group containing polymeric compound or a stabilizing effective amount of an amino-group containing polymeric compound, or combination thereof; wherein said stabilized pharmaceutical composition does not contain a stabilizing effective amount of another stabilizer or a combination of other stabilizers.

- B3
36. (Amended) A stabilized pharmaceutical composition comprising an active component consisting essentially of pravastatin sodium and about 40% or greater by weight of the composition of an amido-group or amino-group containing polymeric stabilizer.